Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Clopidogrel Hypersensitivity: Pathogenesis, Presentation and Diagnosis

Author(s): Megan K. Ford* and John R. Cohn

Volume 17, Issue 2, 2019

Page: [110 - 112] Pages: 3

DOI: 10.2174/1570161116666181031143628

Price: $65

Abstract

This paper provides an overview of the pathogenesis, presentation and diagnosis of clopidogrel hypersensitivity. The majority of clopidogrel hypersensitivity cases are due to a T cell mediated Gell and Coombs Type IV reaction. History, histology, and patch testing have shown consistency with a T cell mediated mechanism. Clopidogrel reactions most commonly present as a mild delayed maculopapular erythematous rash 5 to 10 days after introduction of the drug, and do not always require discontinuation of the drug. Severe cutaneous, systemic, and immediate adverse reactions to clopidogrel are rare. For the diagnosis of clopidogrel hypersensitivity, drug causality can be determined using patch testing, or for mild reactions, recurrence of symptoms after drug reintroduction, although neither are required for diagnosis.

Keywords: Clopidogrel, hypersensitivity, pathogenesis, diagnosis, clopidogrel allergy, drug allergy.

« Previous Next »
Graphical Abstract

[1]
Cohn JR, Savage MP, Cutlip D. Hypersensitivity reactions to clopidogrel UpToDate Topic 82798 Version 80 Available from: https://www.uptodate.com/contents/hypersensitivity-reactions-to-clopidogrel [Accessed on 4 September 2018].
[2]
Cheema AN, Mohammad A, Hong T, et al. Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation. J Am Coll Cardiol 2011; 58(14): 1445-54.
[3]
Doogue MP, Begg EJ, Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc 2005; 80: 1368.
[4]
Kanadiya MK, Singhal S, Koshal VB. Prasugrel as a safe alternative for clopidogrel-associated arthritis. J Invasive Cardiol 2011; 23(6): 137-8.
[5]
Campbell KL, Cohn JR, Savage MP. Clopidogrel hypersensitivity: Clinical challenges and options for management. Expert Rev Clin Pharmacol 2010; 3(4): 553-61.
[6]
Doshi R, Enoh A, Antonopoulos P, Sattar P. A novel, accelerated method of desensitization in a patient with a documented hypersensitivity reaction to clopidogrel. J Cardiol Cases 2010; 1(3): 158-60.
[7]
Chopra P, Prashant V, Klaustermeyer WB. Successful use of prasugrel, an alternative antiplatelet agent, in a patient with clopidogrel allergy. Ann Allergy Asthma Immunol 2011; 107(6): 541-2.
[8]
von Tiehl KF, Price MJ, Valencia R, Ludington KJ, Teirstein PS, Simon RA. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007; 50(21): 2039-43.
[9]
Ghosh SK, Bandyopadhyay D. Clopidogrel-induced fixed drug eruption. J Eur Acad Dermatol Venereol 2009; 23(10): 1202-3.
[10]
Meissner M, Beier C, Wolter M, Kaufmann R, Gille J. Suberythrodermic pustular psoriasis induced by clopidogrel. Br J Dermatol 2006; 155(3): 630.
[11]
Shetty RK1. Madken M, Naha K, Vivek G. Leucocytoclastic vasculitis as a late complication of clopidogrel therapy. BMJ Case Rep 2013; 2013: bcr2012007861.
[12]
Erpolat S, Nazli Y, Colak N, Yenidunya S. Leukocytoclastic vasculitis associated with clopidogrel. Cutan Ocul Toxicol 2012; 31(2): 171-3.
[13]
Ulman CA, Palmer DG, Trevino JJ, Olsen TG, Krishnamurthy S, Gandhi RK. Acute generalized exanthematous pustulosis induced by clopidogrel. Int J Dermatol 2014; 53(10): 461-2.
[14]
Ellerbroek JC, Cleveland MG. Clopidogrel-associated acute generalized exanthematous pustulosis. Cutis 2011; 87: 181-5.
[15]
Nakamizo S, Kobayashi S, Usui T, Miyachi Y, Kabashima K. Clopidogrel‐induced acute generalized exanthematous pustulosis with elevated Th17 cytokine levels as determined by a drug lymphocyte stimulation test. Br J Dermatol 2010; 162(6): 1402-3.
[16]
Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47(1): 175-81.
[17]
Jeung YJ, Lee JY, Oh MJ, Choi DC, Lee BJ. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and Stevens-Johnson syndrome. Allergy Asthma Immunol Res 2010; 2(2): 123-6.
[18]
Trivier JM, Caron J, Mahieu M, Cambier N, Rose C. Fatal aplastic anaemia associated with clopidogrel. Lancet 2001; 357(9254): 446.
[19]
Meyer B, Staudinger T, Lechner K. Clopidogrel and aplastic anaemia. Lancet 2001; 357(9266): 1446-7.
[20]
Akcay A, Kanbay M, Agca E, Sezer S, Ozdemir FN. Neutropenia due to clopidogrel in a patient with end-stage renal disease. Ann Pharmacother 2004; 38(9): 1538-9.
[21]
Suh SY, Rha SW, Kim JW, et al. Neutropenia associated with clopidogrel use in a patient with chronic renal failure who underwent percutaneous coronary and peripheral intervention. Int J Cardiol 2006; 112(3): 383-5.
[22]
McCarthy MW, Kockler DR. Clopidogrel-associated leukopenia. Ann Pharmacother 2003; 37(2): 216-9.
[23]
Elmi F, Peacock T, Schiavone J. Isolated profound thrombocytopenia associated with clopidogrel. J Invasive Cardiol 2000; 12(10): 532-5.
[24]
Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342(24): 1773-7.
[25]
Phillips EJ, Knowles SR, Shear NH. Serum sickness-like reaction associated with clopidogrel. Br J Clin Pharmacol 2003; 56(5): 583.
[26]
Khan EA, Blake JW, Stamp LK. Ticlopidine as a safe alternative for clopidogrel-associated arthritis. J Rheumatol 2009; 36(4): 855.
[27]
Boulman N, Rozenbaum M, Slobodin G, Rosner I. Acute polyarthritis associated with clopidogrel treatment. IMAJ 2005; 7(10): 670.
[28]
Williams MF, Maloof JA. Resolution of clopidogrel-associated polyarthritis after conversion to prasugrel. Am J Health Syst Pharm 2014; 71(13): 1097-100.
[29]
Agrawal S, Harburger J, Stallings G, Agrawal N, Garg J. Clopidogrel-induced recurrent polyarthritis. J Investig Med High Impact Case Rep 2013; 1(3): 2324709613500239.
[30]
Kanadiya MK, Singhal S, Koshal VB. Prasugrel as a safe alternative for clopidogrel-associated arthritis. J Invasive Cardiol 2011; 23: 137-8.
[31]
Garg A, Radvan J, Hopkinson N. Clopidogrel associated with acute arthritis. BMJ 2000; 320(7233): 483.
[32]
Tayyareci Y. Acute arthritis associated with loading dose of clopidogrel. J Clin Rheumatol 2008; 14(4): 254-5.
[33]
Chen KK, Ginges I, Manolios N. Clopidogrel‐associated acute arthritis. Intern Med J 2003; 33(12): 618-9.
[34]
Liping Z, Bin H, Qiming F. An extraordinary case associated with an allergic reaction to clopidogrel: Coronary artery spasm or kounis syndrome? Heart Lung Circ 2015; 24(11): 180-3.
[35]
Green D. CAPRIE trial. Lancet 1997; 349(9048): 354-5.
[36]
Plavix (clopidogrel) [package insert]. Bridgewater (NJ): Sanofiaventis; 2016.
[37]
Vigo PG, MacDowell AL, Wedner HJ. Successful desensitization with clopidogrel after a positive skin test. Ann Allergy Asthma Immunol 2005; 94(1): 132.

Rights & Permissions Print Cite
Article Metrics
41
3
© 2024 Bentham Science Publishers | Privacy Policy